24. A multispecific molecule according to any one of claims 11 to 23 in which one or more amino acids in one or more CDRs have been substituted with another amino acid.
25. A multispecific molecule according to claim 24 wherein one or more cysteine residues has been substituted with another amino acid.
26. A multispecific molecule according to claim 24 or claim 25 wherein one or more aspartic acid isomerisation sites and/or asparagine deamidation sites and/or glycosylation sites has been removed by substituting one or more amino acids in one or more CDRs.
27. A multispecific molecule according to any one of claims 1-26, which further comprises a binding domain specific to serum albumin, such as human serum albumin.
28. A composition comprising one or more multispecific proteins as defined in any one of claims 1 to 27.
29. A nucleotide sequence encoding a multispecific protein or component thereof as defined in any one of claims 1 to 27.
30. A vector comprising a nucleotide sequence defined in claim 29.
31. A multispecific protein according to any one of claims 1 to 27 or a composition according to claim 28, for use in therapy.
32. Use of a multispecific protein according to any one of claims 1 to 27 or a composition according to claim 28, for the manufacture of a medicament for use in therapy, in particular for the treatment of a condition or disorder described herein.
33. A method of treating a patient comprising the administration of a therapeutically effective amount of a multispecific protein according to any one of claims 1 to 27 or a composition according to claim 28.